Cargando…
Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHA(2)DS(2)-VASc Score
BACKGROUNDS: The clinical benefit of ticagrelor vs. clopidogrel in unselected patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) remains controversial in the real world. This study was aimed to investigate the impact of ticagrelor vs. clopidogrel in subjects w...
Autores principales: | Na, Kun, Qiu, Miaohan, Ma, Sicong, Li, Yi, Li, Jing, Liu, Rong, Zhang, Jiaoyang, Han, Yaling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013766/ https://www.ncbi.nlm.nih.gov/pubmed/35445091 http://dx.doi.org/10.3389/fcvm.2022.808571 |
Ejemplares similares
-
CHA2DS2-VASc Score Predict No-Reflow Phenomenon in Primary Percutaneous Coronary Intervention in Primary Percutaneous Coronary Intervention
por: Mirbolouk, Fardin, et al.
Publicado: (2018) -
CHA(2)DS(2)-Vasc score and CHA(2)DS(2)-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents
por: Zhao, Sheng Gang, et al.
Publicado: (2019) -
Risk stratification using the CHA(2)DS(2)-VASc score in patients with coronary heart disease undergoing percutaneous coronary intervention; sub-analysis of SHINANO registry()
por: Hioki, Hirofumi, et al.
Publicado: (2015) -
CHA(2)DS(2)-VASc score as predictor of ischemic stroke in patients undergoing coronary artery bypass grafting and percutaneous coronary intervention
por: Tian, Yaohua, et al.
Publicado: (2017) -
CHA(2)DS(2)-VASc score for in-hospital recurrence risk stratification in patients with myocardial infarction
por: Pang, Hui, et al.
Publicado: (2022)